{"entity":{"id":"paper-qi-orimiracle-gastrointestinal-cancer-med-2023","kind":"paper","name":"Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay","aka":[],"tldr":"A personalised blood test from OrigiMed found leftover cancer before and after surgery for stomach and bowel cancer.","summary":"OriMIRACLE S identifies tumour-specific variants by whole-exome sequencing of tumour and germline DNA, selects clonal SNVs with the OriSelector algorithm for patient-specific multiplex PCR panels, and calls a sample positive when three sites are detected, giving nearly 100 per cent sample-level sensitivity and specificity with panels of 21 to 30 variants. In 127 patients with gastrointestinal tumours, residual disease was positive before surgery in 18 of 26 and after surgery in 24 of 82; positivity was 33.33 per cent in gastric adenocarcinoma and 32.26 per cent in colorectal cancer.","asOf":"2026-11-04","links":[{"label":"Qi et al., Cancer Med 2023","url":"https://doi.org/10.1002/cam4.6286"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37602656/"}],"tags":[],"related":[],"cancers":["gastric","colorectal"],"sections":["diagnostics"],"technologies":["mrd-testing"],"targets":[],"drugs":["orimiracle-s"],"companies":["origimed"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-medicine"],"dependsOn":[],"notes":[],"journal":"Cancer Medicine","year":2023,"doi":"10.1002/cam4.6286","pmid":"37602656","authors":"Qi Z, Li Y, Wang Z, et al.","paperType":"methods","findings":["Panels of 21 to 30 clonal variants; positive when three sites detected.","Positive before surgery in 18 of 26; after surgery in 24 of 82."],"whatItMeans":"A residual disease test built on clonal variants only, which detects the trunk of the tumour and by design not its branches.","caveats":["No limit of detection stated in the abstract."],"participants":127},"route":"/key-papers/paper-qi-orimiracle-gastrointestinal-cancer-med-2023/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"orimiracle-s","kind":"drug","name":"OriMIRACLE S","route":"/drugs/orimiracle-s/"}],"company":[{"id":"origimed","kind":"company","name":"OrigiMed","route":"/companies/origimed/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"journal":[{"id":"cancer-medicine","kind":"journal","name":"Cancer medicine","route":"/journals/cancer-medicine/"}]}}